Journal Information
Vol. 40. Issue 8.
Pages 386 (August 2004)
Letters to the Editor
Full text access
Author's Reply
Visits
3601
I. Sampablo Lauroa, J.I. Izquierdob
a Servicio de Neumología, Hospital Sagrat Cor, Barcelona, Spain
b Servicio de Neumología, Hospital General, Guadalajara, Spain
This item has received
Article information
Full text is only available in PDF
REFERENCES
[1]
DR Shalinsky, J Brekken, H Zou.
Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non small cell lung cancer tumors: single agent and combination chemotherapy studies.
Clin Cancer Res, 5 (1999), pp. 1905-1917
[2]
C Richardson, R Sharma, G Cox, K O'Byrne.
Epidermal growth factor receptor and cyclooxygenase-2 in non-small cell lung cancer: potential targets for chemoprevention and treatment.
Lung Cancer, 39 (2003), pp. 1-13
[3]
I Sampablo Lauro, JL Izquierdo.
¿Cuál debe ser el papel del neumólogo en el tratamiento quimioterapéutico del cáncer de pulmón?.
Arch Bronconeumol, 39 (2003), pp. 483-484
[4]
J Dijkman, J Martínez Gonzáles del Río, R Loddenkemkper, K Prowse, N Siafakas.
Report of the working party of the “UEMS Monospeciality section on Pneumology” on training requirements and facilities in Europe.
Eur Respir J, 7 (1994), pp. 1019-1022
[5]
L Hyde, C Hyde.
Clinical manifestations of lung cancer.
Chest, 65 (1974), pp. 299-306
Copyright © 2004. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?